Bayer HealthCare announced that the U.S. Food and Drug Administration (FDA) has approved Gadavist (gadobutrol) injection for use with magnetic resonance imaging (MRI) in pediatric patients less than 2 years of age, including term neonates, to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system.
A study that identifies new heart attack risk factors and supports the use of a blood test for detection in patients will be published in the AACE (American Association of Clinical Endocrinologists) Journal.
As many as 500,000 people in the United States have a heritable and potentially fatal heart disease called hypertrophic cardiomyopathy.
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
InspireMD, Inc. announced results from two important clinical trials. Thirty-day results from the MASTER II trial, which enrolled 310 of a planned 1,114 patients were presented at a major cardiology congress in Israel in December. The trial was suspended in October 2014 as a result of a corporate shift in strategy to a next-generation MGuard drug eluting stent (DES) platform. The company also announced ipsilateral diffusion weighted magnetic resonance imaging (DW-MRI) results from the CARENET Trial for the CGuard system which successfully completed enrollment in July.
Sorin Group announced U.S. Food and Drug Administration (FDA) clearance for Memo 3-D ReChord, a semi-rigid annuloplasty ring for mitral valve repair.
The issue of sudden cardiac death has long been a concern of heart specialists, for cardiac arrest often hits young, apparently healthy and athletic people out of the blue.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
The first large-scale, multispecialty prospective clinical research trial to evaluate the use of inferior vena cava (IVC) filters and related follow-up treatment in the United States is set to enroll the first patient in spring 2015 with participation from seven filter manufacturers.
The U.S. Food and Drug Administration (FDA) has cleared Medtronic’s In.Pact Admiral drug-coated balloon (DCB) for the interventional treatment of peripheral artery disease (PAD) for the superficial femoral and popliteal arteries in the upper leg. This is the second drug-eluting balloon (DEB) cleared by the FDA, the first being C. R. Bard’s Lutonix 035 approved in November.
New data from the Boston Scientific clinical trial program of the Lotus Valve System continue to demonstrate strong performance as a less invasive treatment for patients with severe aortic stenosis who are considered high risk for surgical valve replacement.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
Patients who were obese before developing heart failure lived longer than normal weight patients with the same condition according to a new study in the Journal of the American College of Cardiology that examined the “obesity paradox” by following obese and non-obese heart failure patients for more than a decade.
Ongoing clinical trials of bioresorbable stents continue to show positive data for the devices, which are widely expected to overtake metallic stents in the coming years if the data trend continues. New data from TCT 2014 further reinforces this.
Reva Medical initiated patient enrollment with its Fantom bioresorbable drug-eluting scaffold.
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
Roxwood Medical Inc. announced U.S. Food and Drug Administration (FDA) clearance for the U.S. commercialization of its CenterCross Catheter for use in the coronary and peripheral vasculature.
Innovative Cardiovascular Solutions LLC has completed a Class A Unit financing totaling $5 million to fund its Emblok Embolic Protection Catheter.
Transcatheter Technologies GmbH announced that it has expanded the Trinity technology platform to include a transfemoral version.